What is claimed is:

- 1. A pharmaceutical composition comprising (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) fluticasone propionate.
- 2. A composition according to claim 1 comprising a mixture of effective amounts of (A) and (B) together with a pharmaceutically acceptable carrier.
- 3. A composition according to claim 1, in which (A) is formoterol fumarate.
- 4. A composition according to claim 3, in which formoterol fumarate is in the form of the dihydrate thereof.
- 5. A composition according to claim 1, which is in inhalable form.
- .6. A composition according to claim 4, which is in inhalable form.
- 7. A composition according to claim 5, which is an aerosol comprising a mixture of (A) and (B) in solution or dispersion in a propellant.
- 8. A composition according to claim 7, in which (A) and (B) are in suspension in said propellant, which is a halogen-substituted hydrocarbon.
- 9. A composition according to claim 8, in which (A) and (B), or each of (A) and (B), has an average particle diameter of up to 10µm.
- 10. A composition according to claim 5, which is a nebulizable composition comprising a dispersion of (A) and (B) in an aqueous, organic or aqueous/organic medium.
- 11. A composition according to claim 5, which is a dry powder comprising finely divided (A) and (B) optionally together with a pharmaceutically acceptable carrier in finely divided form.
- 12. A composition according to claim 11, in which the carrier is present and is a saccharide.
- 13. A composition according to claim 12, in which the carrier is lactose.

- 14. A composition according to claim 11 in which (A) or (B), or each of (A) and (B), has an average particle diameter of up to $10 \mu m$.
- 15. A composition according to claim 1, in which the weight ratio of (A) to (B) is from 3:1 to 1:3000.
- 16. A composition according to claim 15, in which said ratio is from 1:5 to 1:50.
- 17. A composition according to claim 15, in which said ratio is from 1:10 to 1:25.
- 18. A composition according to claim 1, which is a dry powder in a capsule, the capsule containing from 3 to 36 µg of (A) as formoterol fumarate dihydrate, from 25 to 500 µg of (B) and a pharmaceutically acceptable carrier in an amount to bring the total weight of dry powder to between 5 mg and 50 mg.
- 19. A composition according to claim 1, which is a dry powder comprising, by weight, 3 to 36 parts of (A) as formoterol fumarate dihydrate, 25 to 500 parts of (B) and 4464 to 24972 parts of a pharmaceutically acceptable carrier.
- 20. A method of treating an inflammatory or obstructive airways disease which comprises administering to a subject in need of such treatment an effective amount of a composition according to claim 1.